News

Tina Valbh explains how disengagement and patient abandonment reveal gaps in support programs.

Pharma can optimize DTP strategies by leveraging data on affordability and patient behavior.

How the zero-prefix collision will disrupt reimbursement, patient access, brand protection and market intelligence — and what commercial leaders must do before 2033.

In today's Pharma Pulse, the FDA flags misleading promotional claims from ImmunityBio regarding its cancer therapy and MedImpact launches new solutions to address the skyrocketing employer costs of GLP-1 weight management therapies.

Corey Ford, principal at Nuvera, explains how pharma is shifting focus from HCPs to patients in support programs and commercialization.

Nareda Mills, global president of Patient Solutions at Inizio Engage, discusses how patient services are measured and which metrics demonstrate value to leadership.

New Benefit 360 and Direct Fund models aim to bridge the gap between clinical eligibility and employer-sponsored coverage.

In today’s Pharma Pulse, industry leaders warn of serialization security issues and pharma companies brace for the 2033 NDC shift.

Workflow alignment, e-prescribing integration, and behavior change strategies are critical to reducing friction across the direct-to-patient ecosystem.

From KPI clarity to right-sized staffing, Kimberly Howard explains how to measure true FRM impact and build flexible models that adapt to market realities.

In today's Pharma Pulse, the FDA grants expanded approval for Imcivree, while new research highlights how optimizing pharmacy technician roles can significantly boost vaccine access and uptake.

Fragmented handoffs and poor communication can leave patients navigating delays and confusion in prior authorization workflows.

Jordan Armstrong outlines how adaptable DTP programs can reduce barriers and accelerate patient access to therapy.

Building climate-resilient cold chains with AI, smarter logistics, and collaboration to ensure safe delivery in a warming world.

Shifting cost dynamics and infrastructure capabilities are prompting manufacturers to reassess traditional distribution channels.

Brok Vandersteen explains how life sciences companies can strategically adopt DTP models for better patient access and commercial success.

Kristine McGaughey, vice president of Implementation at ConnectiveRx, shares her insights on timing, strategy, and planning to ensure a smooth therapy launch.

In today's Pharma Pulse, the FDA grants a 54-day fast-track approval for high-dose Wegovy under a new priority program while a new report explores the economic pressures and chronic shortages destabilizing the U.S. generics market

Kimberly Howard, senior manager of Field Reimbursement Services at CoverMyMeds, explains how aligning hubs and reimbursement teams improves patient support.

Chronic shortages expose how low prices, fragile supply chains, and misaligned incentives are undermining the U.S. generic drug market.

Tina Valbh, managing partner at PharmaKonnect and co-founder of Tina’s Warriors, discusses the biggest post therapy launch patient support gaps.

In today's Pharma Pulse, the FDA approves Icotyde as the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis, while Cold Chain Technologies prepares to debut its MedAssure orchestration platform at LogiPharma 2026

Jordan Armstrong, VP of Business Development at AssistRX, explains how companies can tailor direct-to-patient strategies into their commercialization plans.

Brok Vandersteen, VP of Business Development, AssistRX, explains how policy pressures push life sciences companies toward direct-to-patient model adoption.

Cold Chain Technologies will debut its MedAssure orchestration platform at LogiPharma 2026 providing a proactive solution for a cold chain market burdened by frequent temperature excursions.

Jay Bregman, founder and CEO of Andel, discusses how employers are managing rising costs for prescription benefits and how pharma companies are shifting their distribution patterns.

In today's Pharma Pulse, ongoing conflict in the Middle East disrupts critical pharmaceutical cold chains, while AstraZeneca and partners launch a new program to decarbonize industrial heat across global supply chains.